Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

PURPOSE: Tumor-derived cell-free DNA (cfDNA) from urine of patients with cancer offers non-invasive biologic material for detection of cancer-related molecular abnormalities such as mutations in Exon 2 of KRAS. EXPERIMENTAL DESIGN: A quantitative, mutation-enrichment next-generation sequencing test...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Fujii, Takeo, Barzi, Afsaneh, Sartore-Bianchi, Andrea, Cassingena, Andrea, Siravegna, Giulia, Karp, Daniel D., Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Huang, Helen J., Veronese, Silvio, Di Nicolantonio, Federica, Pingle, Sandeep, Vibat, Cecile Rose T., Hancock, Saege, Berz, David, Melnikova, Vladislava O., Erlander, Mark G., Luthra, Rajyalakshmi, Kopetz, E. Scott, Meric-Bernstam, Funda, Siena, Salvatore, Lenz, Heinz-Joseph, Bardelli, Alberto, Janku, Filip
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5511562/
https://ncbi.nlm.nih.gov/pubmed/28096270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2592
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires